UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 16, 2020

Solid Biosciences Inc.

(Exact Name of Registrant as Specified in Charter)

141 Portland Street, Fifth Floor

Cambridge, MA 02139

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (617) 337-4680

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 16, 2020, Andrey Zarur notified Solid Biosciences Inc. (the “Company”) of his decision to resign as Chairman of the Board of Directors of the Company (the “Board”) and as a member of the Board, effective immediately. Dr. Zarur’s decision to resign from the Board was not due to a disagreement on any matter related to the Company’s operations, policies or practices. Following Dr. Zarur’s resignation, on June 16, 2020, the Board appointed Ian Smith as Chairman of the Board.

(e) The Company held its Annual Meeting of Stockholders on June 16, 2020 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the Solid Biosciences Inc. 2020 Equity Incentive Plan (the “Plan”), which had previously been approved by the Board, subject to stockholder approval.

A description of the material terms and conditions of the Plan is set forth in “Proposal No. 3—Approval of the Solid Biosciences Inc. 2020 Equity Incentive Plan” of the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April  28, 2020, and is incorporated herein by reference. A complete copy of the Plan is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting to consider and vote upon the matters listed below. The following is a summary of the matters voted on at that meeting.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

99.1 Solid Biosciences Inc. 2020 Equity Incentive Plan

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.